Prostate-specific antigen and other markers of therapeutic response

Research output: Contribution to journalArticle

Abstract

Several new agents and combinations demonstrate significant activity in the treatment of patients with hormone refractory prostate cancer. Prostate- specific antigen (PSA) is being used increasingly as the key marker of a therapeutic response in trials of new agents. This article reviews data that support this marker as a surrogate endpoint, and it discusses the issues around the appropriateness of PSA as an intermediate marker with evolving noncytotoxic agents. Other biomarkers of prostate cancer progression are not uniformly elevated in men with advanced disease; to date, they are of limited clinical use. This article also discusses the rationale and results of novel and alternative biomarkers of prostate cancer progression.

Original languageEnglish (US)
Pages (from-to)291-302
Number of pages12
JournalUrologic Clinics of North America
Volume26
Issue number2
DOIs
StatePublished - 1999

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Biomarkers
Therapeutics
Hormones

ASJC Scopus subject areas

  • Urology

Cite this

Prostate-specific antigen and other markers of therapeutic response. / Carducci, Michael A; DeWeese, Theodore; Nelson, J. B.

In: Urologic Clinics of North America, Vol. 26, No. 2, 1999, p. 291-302.

Research output: Contribution to journalArticle

@article{bcefec5b031d46e7a4ba5e7fd526a63f,
title = "Prostate-specific antigen and other markers of therapeutic response",
abstract = "Several new agents and combinations demonstrate significant activity in the treatment of patients with hormone refractory prostate cancer. Prostate- specific antigen (PSA) is being used increasingly as the key marker of a therapeutic response in trials of new agents. This article reviews data that support this marker as a surrogate endpoint, and it discusses the issues around the appropriateness of PSA as an intermediate marker with evolving noncytotoxic agents. Other biomarkers of prostate cancer progression are not uniformly elevated in men with advanced disease; to date, they are of limited clinical use. This article also discusses the rationale and results of novel and alternative biomarkers of prostate cancer progression.",
author = "Carducci, {Michael A} and Theodore DeWeese and Nelson, {J. B.}",
year = "1999",
doi = "10.1016/S0094-0143(05)70069-0",
language = "English (US)",
volume = "26",
pages = "291--302",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Prostate-specific antigen and other markers of therapeutic response

AU - Carducci, Michael A

AU - DeWeese, Theodore

AU - Nelson, J. B.

PY - 1999

Y1 - 1999

N2 - Several new agents and combinations demonstrate significant activity in the treatment of patients with hormone refractory prostate cancer. Prostate- specific antigen (PSA) is being used increasingly as the key marker of a therapeutic response in trials of new agents. This article reviews data that support this marker as a surrogate endpoint, and it discusses the issues around the appropriateness of PSA as an intermediate marker with evolving noncytotoxic agents. Other biomarkers of prostate cancer progression are not uniformly elevated in men with advanced disease; to date, they are of limited clinical use. This article also discusses the rationale and results of novel and alternative biomarkers of prostate cancer progression.

AB - Several new agents and combinations demonstrate significant activity in the treatment of patients with hormone refractory prostate cancer. Prostate- specific antigen (PSA) is being used increasingly as the key marker of a therapeutic response in trials of new agents. This article reviews data that support this marker as a surrogate endpoint, and it discusses the issues around the appropriateness of PSA as an intermediate marker with evolving noncytotoxic agents. Other biomarkers of prostate cancer progression are not uniformly elevated in men with advanced disease; to date, they are of limited clinical use. This article also discusses the rationale and results of novel and alternative biomarkers of prostate cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=0032914495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032914495&partnerID=8YFLogxK

U2 - 10.1016/S0094-0143(05)70069-0

DO - 10.1016/S0094-0143(05)70069-0

M3 - Article

C2 - 10361552

AN - SCOPUS:0032914495

VL - 26

SP - 291

EP - 302

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 2

ER -